Inclusion Criteria
Patients must have:
- HIV seropositivity by commercially available ELISA.
- Meet Disease Status criteria.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Concurrent neoplasms other than basal cell carcinoma of the skin, in-situ carcinoma of the cervix or limited cutaneous Kaposi's sarcoma.
- Recently treated HIV-related lymphoma.
- Major organ allograft.
- Presence of space occupying central nervous system (CNS) lesions or other conditions which would be anticipated to cause cerebral edema.
- Renal compromise or use of drug therapy anticipated to lead to renal compromise.
- Active opportunistic infection requiring hospitalization or exclude medication.
- Requiring continual acyclovir for suppression of herpes infection.
Concurrent Medication:
Excluded:
- Acyclovir.
- Drug therapy anticipated to lead to renal compromise.
Patients with the following are excluded:
- Intolerance to zidovudine (AZT) at 300 mg/day divided q8h or didanosine (ddI) at 7 mg/kg/day given twice a day.
- History of HIV-related lymphoma.
- History of asthma requiring frequent therapy, chronic pulmonary disease, hypertension requiring therapy, or congestive heart failure.
- Any of the symptoms or conditions listed in Exclusion - Co-Existing Conditions.
Prior Medication:
Excluded:
- Any prior therapy with interleukin-2 (IL-2) or PEG IL-2.
Excluded 30 days prior to study entry:
- Treatment with other anti-HIV medication or known immunomodulators or other chemotherapy or radiation therapy.
Active substance abuse so patients would be anticipated to be poorly compliant with protocol requirements.
Purpose
